European Court of Justice deliberation on stem cell based therapies
The European Court of Justice (ECJ) is deliberating on the patentability of cell therapies based on stem cells. The General Advocate of the Court of Justice of the European Union has recommended the following: “An invention must be excluded from patentability where the application of the technical process for which the patent is filed necessitates the prior destruction of human embryos or their use as base material, even if the description of that process does not contain any reference to the use of human embryos ”.
Austin Smith and 12 other coordinators of European Networks, including Marc Peschanski, David Sassoon, Catherine Verfaillie and Juergen Hescheler, among others, have addressed a correspondence to Nature, aiming at alerting the international community and the public authorities (in particular European) on the fact that the General Advocate of the ECJ recommendation would lead to an important backward step of researchers capacities for stem cells valorisation in Europe. The correspondence will appear in Nature next Thursday April 28th and a letter to will be adressed to the concerned Scientific Officers of the European Commission.
For additional information, please download:
Last changed: 06/27/2011